< Back to previous page
Researcher
Frans Van de Werf
- Disciplines:Cardiac and vascular medicine
Affiliations
- Cardiology (Division)
Member
From1 Oct 1999 → 30 Sep 2020
Projects
1 - 6 of 6
- MicroRNAs, the new therapy for tomorrow's failing heart.From1 Oct 2011 → 1 Nov 2014Funding: FWO fellowships
- MicroRNAs in heart failure.From1 May 2011 → 30 Apr 2012Funding: BOF - Other initiatives
- The role of micro-RNA -221 and -222 in the pathophysiology of viral myocarditisFrom1 Oct 2010 → 22 Mar 2016Funding: FWO fellowships
- Matricellular proteins, Thrombospondin-2 en SPARC (Osteonectine) protect against heart failure.From1 Oct 2009 → 30 Sep 2012Funding: FWO fellowships
- The cardiac matrix, a vital regulator of inflammation during viral myocarditis.From1 Jan 2009 → 31 Dec 2012Funding: FWO research project
- Matricellular proteins, thrombospondin-2 and SPARC (osteonectin), protect against heart failure.From1 Oct 2008 → 30 Sep 2009Funding: BOF - Other initiatives
Publications
1 - 10 of 334
- STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial(2024)
Authors: Frans Van de Werf, Peter Sinnaeve
Pages: 727 - 728 - STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial(2023)
Authors: Frans Van de Werf, Katleen Vandenberghe, Kris Bogaerts, Peter Sinnaeve
Pages: 753 - 764 - Polypill Strategy in Secondary Cardiovascular Prevention(2022)
Authors: Frans Van de Werf
Pages: 967 - 977 - Sex differences in mortality after an acute coronary syndrome increase with lower country wealth and higher income inequality(2022)
Authors: Frans Van de Werf
Pages: 392 - 400 - Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial(2021)
Authors: Frans Van de Werf
- Do clinical trial data suggest a role for SGLT2-inhibitors in primary prevention of heart failure and chronic kidney disease?(2021)
Authors: Jan A Staessen, Frans Van de Werf
- Number of Antithrombotic Drugs Used Early and In-hospital Outcomes in Acute Coronary Syndromes(2021)
Authors: Frans Van de Werf
Pages: 790 - 798 - Trends in reperfusion therapy for acute ST-segment elevation myocardial infarction in an academic percutaneous coronary intervention center in the metropolitan area of a developing country: insights from the Jakarta Acute Coronary Syndrome registry(2021)
Authors: Frans Van de Werf
Pages: 466 - 467 - Long-Term Antithrombotic Therapy and Clinical Outcomes in Patients with Acute Coronary Syndrome and Renal Impairment: Insights from EPICOR and EPICOR Asia(2021)
Authors: Frans Van de Werf
Pages: 471 - 482 - Veno-arterial extracorporeal membrane oxygenation (ECMO) in patients with cardiogenic shock: rationale and design of the-label EURO SHOCK trial(2021)
Authors: Tom Adriaenssens, Kris Bogaerts, Frans Van de Werf
Pages: E1227 - U124